Question 1

What is TRASTUZUMAB used for?

Accepted Answer

TRASTUZUMAB (brand name Herceptin) is a HER2-Targeted Therapy indicated for 1 INDICATIONS AND USAGE Herceptin is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer. ( 1.1, cyclophosphamide, in combination with cisplatin and capecitabine or 5-fluorouracil.

Question 2

How does TRASTUZUMAB work?

Accepted Answer

TRASTUZUMAB works through the following mechanism: 12.1 Mechanism of Action The HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor receptor. Herceptin has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumor cells that overexpress HER2. Herceptin is a mediator of antibody-dependent cellular cytotoxicity (ADCC). In vitro , Herceptin-mediated ADCC has been shown to be preferentially exerted on HER2 overexpressing cancer cells compared with cancer cells that do not overexpress HER2..

Question 3

What are the most common side effects of TRASTUZUMAB?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for TRASTUZUMAB. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is TRASTUZUMAB the same as Herceptin?

Accepted Answer

Herceptin is a brand name for TRASTUZUMAB. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

TRASTUZUMAB

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations